BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Xanthus Pharmaceuticals, Inc. 

2020 University Street
Suite 2000
Montreal  Quebec  H3A 2A5  Canada
Phone: 514-843-5959 Fax: 514-843-9941


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Antisoma PLC (ASM.L) Completes Acquisition of Xanthus Pharmaceuticals, Inc. 6/11/2008 10:50:12 AM    More...
Antisoma PLC (ASM.L)'s Acquisition of Xanthus Pharmaceuticals, Inc. Approved by Shareholders 6/10/2008 9:02:56 AM    More...
Xanthus Pharmaceuticals, Inc. Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML 6/2/2008 8:42:44 AM    More...
Antisoma PLC (ASM.L) To Acquire Xanthus Pharmaceuticals, Inc. For USD $52.2M 5/16/2008 8:45:16 AM    More...
Xanthus Pharmaceuticals, Inc.' Symadex Reverses Disease in Preclinical Mouse Models of Multiple Sclerosis 4/16/2008 8:39:16 AM    More...
Xanthus Pharmaceuticals, Inc. Presents Data Supporting Distinctive Mechanism of Action for Xanafide(R) 4/15/2008 8:30:33 AM    More...
Xanthus Pharmaceuticals, Inc. Announces Oral Fludarabine NDA Accepted for Review by U.S. FDA 1/22/2008 8:34:39 AM    More...
Xanthus Pharmaceuticals, Inc. Receives Orphan Drug Designation for Oral Fludarabine for the Treatment of CLL 1/3/2008 8:57:13 AM    More...
Xanthus Pharmaceuticals, Inc.'s Symadex Demonstrates Ability to Increase Spinal Cord Remyelination in Multiple Sclerosis Model 12/11/2007 11:51:54 AM    More...
Xanthus Pharmaceuticals, Inc. Initiates Pivotal Phase 3 Trial of Xanafide in Secondary Acute Myeloid Leukemia 10/8/2007 8:18:20 AM    More...
1234

//-->